Briefs: APL Healthcare, Biocon, USFDA, Sun Pharma and Clean Fino-Chem

USFDA determines Sun Pharma's Baska facility inspection classification as OAI

Eli Lilly reports positive Phase 3 results for oral obesity drug Orforglipron

At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo

Lupin secures SBTi validation for emission reduction targets

Gujarat Kidney and Super Speciality to file IPO at Rs.108- Rs.114 per share

The company operates a chain of mid-sized multi-speciality hospitals

Vanda Pharmaceuticals seeks FDA nod for breakthrough psoriasis drug

Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients

KIMS Hospital Bengaluru commences operations at PES University campus

The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital

Novartis appoints Vrinda Taneja as Director – People & Organisation, International India

Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D

Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide

All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed

Merck wins key EU backing to expand use of PAH Drug WINREVAIR

WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states

Pfizer’s TUKYSA shows major benefit in first-line maintenance for metastatic breast cancer

The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA